# Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy

> **NCT05770531** · PHASE2 · RECRUITING · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 160 (estimated)

## Conditions studied

- Metastatic HER2-Negative Breast Carcinoma
- Metastatic Triple-Negative Breast Carcinoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Biospecimen Collection
- **BIOLOGICAL:** Sacituzumab Govitecan

## Key facts

- **NCT ID:** NCT05770531
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-04
- **Primary completion:** 2028-08-01
- **Final completion:** 2028-10-01
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2025-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05770531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05770531, "Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05770531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*